How optic nerve swelling changes after steroid treatment in giant cell arteritis
Tracks optic nerve swelling after steroids in giant cell arteritis.
Key facts
- Who runs it
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 May 2026
- Expected to end
- 1 May 2029
- Type of study
- Observational
- Treatments tested
- Optic Nerve Sheath Ultrasound
- Temporal artery ultrasound
- Bloodwork : CRP and ESR
- Record updated
- 21 October 2026
Who can take part
The trial is looking for adults with newly diagnosed giant cell arteritis (GCA) who are already in the SONIC-GCA study. Participants have repeated eye ultrasound scans and blood tests during their first 2 months of standard treatment.
- Age
- 50 Years and older
- Sex
- All sexes
- Disease stage
- Newly diagnosed GCA, confirmed by the standard GCA check at the start of SONIC-GCA. The first optic nerve ultrasound in SONIC-GCA must be done.
- Earlier treatment
- Steroids (glucocorticoids) for ≤ 48 hours and ≤ 160 mg prednisone-equivalent at most before the start of the study.
- Main reasons for not taking part
- Taking part at the same time in a blinded drug trial
- Not enrolled in SONIC-GCA
- Not able or willing to give written consent
- Not willing to follow the intensive visit schedule
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Participants must be enrolled in SONIC-GCA and must have:; completed the baseline optic nerve sheath ultrasound; confirmed GCA as determined by the baseline standardized GCA assessment in SONIC-GCA
- Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline
- Ability and willingness to provide written informed consent
- Agreement to complete the SONIC-TIME intensive follow-up schedule
Who cannot take part
- Concurrent participation in a blinded interventional pharmaceutical clinical trial
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.
Read full original descriptionShow less
The SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.
Sixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.
The primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.
The group in the trial
- GCA group
Patients with new-onset GCA who completed the SONIC-GCA (main study) baseline visit and who received 48 hours or less of glucocorticoids and less or equal to 160mg of oral prednisone equivalent. Study visits : Baseline, then days 3, 7, 10, 14, 21, 28, and Month 2
Treatment: Optic Nerve Sheath Ultrasound, Temporal artery ultrasound, and Bloodwork : CRP and ESR
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis
- Plain-language title
- How optic nerve swelling changes after steroid treatment in giant cell arteritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07508514, who can take part
- Record updated
- 21 October 2026